Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the Olanzapine Poor Response Predictor Genetic Signature
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic signature are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the genetic signature.
